144 related articles for article (PubMed ID: 34655919)
1. Proposal of selective inhibitor for bacterial zinc metalloprotease: Molecular mechanics and ab initio molecular orbital calculations.
Imai K; Saito R; Ezawa T; Sugiyama S; Sylte I; Kurita N
J Mol Graph Model; 2022 Jan; 110():108047. PubMed ID: 34655919
[TBL] [Abstract][Full Text] [Related]
2. Specific interactions between zinc metalloproteinase and its inhibitors: Ab initio fragment molecular orbital calculations.
Ara A; Kadoya R; Ishimura H; Shimamura K; Sylte I; Kurita N
J Mol Graph Model; 2017 Aug; 75():277-286. PubMed ID: 28618335
[TBL] [Abstract][Full Text] [Related]
3. Design of galardine analogs as putative psudolysin inhibitors based on
Ezawa T; Sugiyama S; Ara A; Sylte I; Kurita N
J Biomol Struct Dyn; 2020 Jul; 38(11):3307-3317. PubMed ID: 31422741
[TBL] [Abstract][Full Text] [Related]
4. Protonation states of central amino acids in a zinc metalloprotease complexed with inhibitor: Molecular mechanics optimizations and ab initio molecular orbital calculations.
Ezawa T; Saito R; Suzuki S; Sugiyama S; Sylte I; Kurita N
Biophys Chem; 2020 Jun; 261():106368. PubMed ID: 32272264
[TBL] [Abstract][Full Text] [Related]
5. The selectivity of galardin and an azasugar-based hydroxamate compound for human matrix metalloproteases and bacterial metalloproteases.
Sylte I; Dawadi R; Malla N; von Hofsten S; Nguyen TM; Solli AI; Berg E; Adekoya OA; Svineng G; Winberg JO
PLoS One; 2018; 13(8):e0200237. PubMed ID: 30075004
[TBL] [Abstract][Full Text] [Related]
6. Water molecule-mediated selective inhibition of bacterial zinc metalloproteinases by non-hydroxamate compounds: Ab initio molecular simulations.
Saito R; Imai K; Takimoto D; Ezawa T; Sugiyama S; Takimoto-Kamimura M; Kurita N
J Mol Graph Model; 2022 Jul; 114():108200. PubMed ID: 35453045
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, experimental evaluation and molecular modelling of hydroxamate derivatives as zinc metalloproteinase inhibitors.
Sjøli S; Nuti E; Camodeca C; Bilto I; Rossello A; Winberg JO; Sylte I; Adekoya OA
Eur J Med Chem; 2016 Jan; 108():141-153. PubMed ID: 26638045
[TBL] [Abstract][Full Text] [Related]
8. Understanding the binding of inhibitors of matrix metalloproteinases by molecular docking, quantum mechanical calculations, molecular dynamics simulations, and a MMGBSA/MMBappl study.
Singh T; Adekoya OA; Jayaram B
Mol Biosyst; 2015 Apr; 11(4):1041-51. PubMed ID: 25611160
[TBL] [Abstract][Full Text] [Related]
9. Computational Approaches to Matrix Metalloprotease Drug Design.
Singh T; Jayaram B; Adekoya OA
Methods Mol Biol; 2017; 1579():273-285. PubMed ID: 28299743
[TBL] [Abstract][Full Text] [Related]
10. Zinc-Chelating Compounds as Inhibitors of Human and Bacterial Zinc Metalloproteases.
Rahman F; Wushur I; Malla N; Åstrand OAH; Rongved P; Winberg JO; Sylte I
Molecules; 2021 Dec; 27(1):. PubMed ID: 35011288
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of bacterial and human zinc-metalloproteases by bisphosphonate- and catechol-containing compounds.
Rahman F; Nguyen TM; Adekoya OA; Campestre C; Tortorella P; Sylte I; Winberg JO
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):819-830. PubMed ID: 33757387
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of pseudolysin and thermolysin by hydroxamate-based MMP inhibitors.
Adekoya OA; Sjøli S; Wuxiuer Y; Bilto I; Marques SM; Santos MA; Nuti E; Cercignani G; Rossello A; Winberg JO; Sylte I
Eur J Med Chem; 2015 Jan; 89():340-8. PubMed ID: 25462250
[TBL] [Abstract][Full Text] [Related]
13. Matrix metalloproteinase inhibitors: a review on pharmacophore mapping and (Q)SARs results.
Kontogiorgis CA; Papaioannou P; Hadjipavlou-Litina DJ
Curr Med Chem; 2005; 12(3):339-55. PubMed ID: 15723623
[TBL] [Abstract][Full Text] [Related]
14. Combined structure- and ligand-based pharmacophore modeling and molecular dynamics simulation studies to identify selective inhibitors of MMP-8.
Kalva S; Vinod D; Saleena LM
J Mol Model; 2014 May; 20(5):2191. PubMed ID: 24756550
[TBL] [Abstract][Full Text] [Related]
15. Tackling Pseudomonas aeruginosa Virulence by a Hydroxamic Acid-Based LasB Inhibitor.
Kany AM; Sikandar A; Yahiaoui S; Haupenthal J; Walter I; Empting M; Köhnke J; Hartmann RW
ACS Chem Biol; 2018 Sep; 13(9):2449-2455. PubMed ID: 30088919
[TBL] [Abstract][Full Text] [Related]
16. Non-Zinc-Binding Inhibitors of MMP-13: GRID-Based Approaches to Rationalize the Binding Process.
Di Pizio A; Agamennone M; Tortorella P
Curr Top Med Chem; 2016; 16(4):449-59. PubMed ID: 26268339
[TBL] [Abstract][Full Text] [Related]
17. Identification of Non-Zinc Binding Inhibitors of MMP-2 Through Virtual Screening and Subsequent Rescoring.
Shamsara J
Drug Res (Stuttg); 2018 Sep; 68(9):529-535. PubMed ID: 29614516
[TBL] [Abstract][Full Text] [Related]
18. Matrix metalloprotease inhibitors: design from structure.
Borkakoti N
Biochem Soc Trans; 2004 Feb; 32(Pt 1):17-20. PubMed ID: 14748704
[TBL] [Abstract][Full Text] [Related]
19. Virtual screening identification and chemical optimization of substituted 2-arylbenzimidazoles as new non-zinc-binding MMP-2 inhibitors.
Laghezza A; Luisi G; Caradonna A; Di Pizio A; Piemontese L; Loiodice F; Agamennone M; Tortorella P
Bioorg Med Chem; 2020 Feb; 28(3):115257. PubMed ID: 31874775
[TBL] [Abstract][Full Text] [Related]
20. Specific interactions between the alkaline protease of P. aeruginosa and its natural peptide inhibitor: ab initio molecular simulations.
Saito R; Imai K; Yamamoto S; Ezawa T; Sugiyama S; Evenseth LSM; Sylte I; Kurita N
J Mol Model; 2021 Dec; 28(1):10. PubMed ID: 34914017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
